Seres Therapeutics Stock In The News

MCRB Stock  USD 13.40  0.31  2.37%   
Our overall analysis of Seres Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Seres Therapeutics. The specific impact of Seres Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Seres Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Seres Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Seres Therapeutics Backtesting and Seres Therapeutics Hype Analysis.
For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.

Seres Therapeutics Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
https://www.globenewswire.com/news-release/2025/07/22/3119304/0/en/Seres-Therapeutics-to-Announce-Second-Quarter-2025-Financial-Results-and-Business-Updates-on-August-6-2025.html
 Bullish
Macroaxis News: globenewswire.com
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
https://www.globenewswire.com/news-release/2025/05/27/3088454/0/en/Seres-Therapeutics-Presents-Expanded-SER-155-Exploratory-Biomarker-Data-at-2025-ASCO-Annual-Meeting.html
 Bullish
Macroaxis News: globenewswire.com
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
https://www.globenewswire.com/news-release/2025/03/13/3042027/0/en/Seres-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Updates.html
 Bullish
Macroaxis News: globenewswire.com
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
https://www.globenewswire.com/news-release/2025/01/16/3010671/0/en/Seres-Therapeutics-Announces-Receipt-of-Expected-50-Million-Installment-Payment-Related-to-VOWST-Sale.html
 Neutral
Yahoo News
11 Oversold NASDAQ Stocks To Buy Right Now
https://finance.yahoo.com/news/11-oversold-nasdaq-stocks-buy-193220134.html
 Bullish
Yahoo News
11 Oversold Healthcare Stocks To Buy Right Now
https://finance.yahoo.com/news/11-oversold-healthcare-stocks-buy-121714179.html
 Bullish
Yahoo News
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://finance.yahoo.com/news/seres-therapeutics-reports-inducement-grants-120000103.html
 Bullish
Yahoo News
Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?
https://finance.yahoo.com/news/halozyme-therapeutics-halo-surges-5-090100581.html
 Bullish
Yahoo News
Seres Therapeutics Announces VOWSTâ„¢ Commercial Launch Update and US FDA Fast Track Designation for SER-155
https://finance.yahoo.com/news/seres-therapeutics-announces-vowst-commercial-120000832.html
 Bullish
Yahoo News
Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
https://finance.yahoo.com/news/seres-therapeutics-participate-42nd-annual-210000751.html
 Neutral

Seres Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Seres and other traded companies coverage with news coverage. We help investors stay connected with Seres headlines for the 24th of July to make an informed investment decision based on correlating the impacts of news items on Seres Stock performance. Please note that trading solely based on the Seres Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Seres Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Seres Therapeutics investors visualize upcoming and past events in order to time the market based on Seres Therapeutics noise-free hype analysis.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Seres Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Seres Therapeutics' short interest history, or implied volatility extrapolated from Seres Therapeutics options trading.
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:
Check out Seres Therapeutics Backtesting and Seres Therapeutics Hype Analysis.
For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.95)
Revenue Per Share
0.871
Quarterly Revenue Growth
(0.93)
Return On Assets
(0.28)
Return On Equity
(15.56)
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.